Progress in molecular targeted drug therapy for hepatocellular carcinoma
Live cancer is the sixth most common malignant tumor in the world,and the incidence rate of hepatocellular carcinoma(HCC)is above 90％.In recent years,due to the influnce of different factors,the incidence rate of HCC has increased year by year,and tends to be younger.HCC has a high incidence rate and mortality.Patients with HCC have no obvious clinical symptoms in the early stage,and the condition of disease develops rapidly.Most of the patients are in the middle and late stage when they see a doctor.After surgical resection,there is still a high recurrence rate.Therefore,systemic chemotherapy plays an important role in the treatment of HCC patients.Molecular targeted drugs are the research hotspot of tumor therapy at present.Compared with traditional chemotherapy drugs,these drugs have higher specificity,targeting and minimal adverse reactions,and are widely used in the treatment of HCC.At present,the commonly used molecular targeted drugs include multi-target kinase inhibitors(sorafenib,regorafenib,lenvatinib),angiogenesis inhibitors(ampatinib,ramolumab,cabozantinib),hepatocyte growth factor inhibitors,immune checkpoint inhibitors.Each drug has its own advantages and disadvantages in the treatment of HCC.This article reviews the progress of molecular targeted drug therapy for HCC,hoping to provide reference for drug therapy of HCC.
万方数据
维普
